Brean Murray Initiates Coverage on Nektar Therapeutics (NKTR) with a Buy; Expect Substantial Value Creation Through Partnerships
Tweet Send to a Friend
Brean Murray initiates coverage on Nektar Therapeutics (Nasdaq: NKTR) with a Buy. Price target $10.
Brean analyst says, "The biggest ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
Brean analyst says, "The biggest ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
